Exhaustive analysis of the P53 gene coding sequence by denaturing gradient gel electrophoresis: application to the detection of point mutations in acute leukemias

Human Mutation
J M PignonM Goossens


We report the set-up of a denaturant gradient gel electrophoresis (DGGE) assay to screen for mutations in the whole coding sequence of the p53 gene. These DGGE experimental conditions were applied to the analysis of the p53 gene in acute leukemias. Forty adults with acute myelogenous leukemia (AML) and 21 with acute lymphoid leukemia (ALL) were investigated. Eleven of the AML patients were investigated at the time of the initial diagnosis and at relapse. In contrast with most reports based on amplified fragments analyzed by single-strand conformation electrophoresis and focusing on exons 5 to 8, we analyzed the whole coding sequence of the gene. Two of the 40 AML patients displayed a point mutation in exon 7; it was either an A to G substitution that converted Tyr-234 to Cys, or a G to A change that converted Arg-248 to Gln. The screening procedure led to the discovery of several intronic and exonic polymorphisms. These results confirm the low incidence of p53 mutations in acute leukemias and suggest a limited role of the p53 protein in leukemogenesis. The computerized modeling and electrophoresis parameters presented here provide a powerful tool for the exhaustive characterization of p53 mutants in all kinds of malignancies.


Jan 1, 1992·Genes, Chromosomes & Cancer·C Caron de Fromentel, T Soussi
Aug 1, 1992·British Journal of Haematology·G HuA B Deisseroth
Feb 25, 1992·Nucleic Acids Research·K BhatiaI T Magrath
Feb 1, 1992·British Journal of Haematology·P FenauxJ P Kerckaert
Dec 11, 1991·Nucleic Acids Research·A MajumdarM M Seidman
Jul 5, 1991·Science·M HollsteinC C Harris
Jun 6, 1991·Nature·A J LevineC A Finlay
Jun 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·G GaidanoR Dalla-Favera
Jan 1, 1990·Genes & Development·D P Lane, S Benchimol
Oct 1, 1990·Molecular and Cellular Biology·J Cheng, M Haas
Jun 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·R G CottonR D Campbell
Feb 7, 1985·Nature·R M MyersT Maniatis

❮ Previous
Next ❯


Jul 29, 1996·International Journal of Cancer. Journal International Du Cancer·A HartmannJ S Kovach
Mar 7, 2002·Journal of Pediatric Hematology/oncology·J GumpS P Hunger
Sep 4, 2007·BMC Cancer·Michael KrypuyAlexander Dobrovic
Nov 26, 2003·Molecular Carcinogenesis·Xabier AgirreJosé L Vizmanos
Jun 20, 1998·Human Mutation·M ProkocimerG Rennert
May 29, 2002·Oncogene·Utz KrugH Phillip Koeffler
Aug 15, 2003·The Journal of General Virology·Manuela Torres-PuenteFernando González-Candelas
Aug 2, 2003·European Journal of Haematology·Claudete Esteves KlumbFranklin David Rumjanek

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.